FHTX
Income statement / Annual
Last year (2023), Foghorn Therapeutics Inc.'s total revenue was $34.16 M,
an increase of 77.63% from the previous year.
In 2023, Foghorn Therapeutics Inc.'s net income was -$98.43 M.
See Foghorn Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$34.16 M
|
$19.23 M
|
$1.32 M
|
$430,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$109.69 M |
$19,228.00 |
$7.52 M |
$57.72 M |
$1.79 M |
$379,000.00 |
| Gross Profit |
-$75.53 M |
$19.21 M |
-$6.20 M |
-$57.29 M |
-$1.79 M |
-$379,000.00 |
| Gross Profit Ratio |
-2.21 |
1 |
-4.7 |
-133.22 |
0 |
0 |
| Research and Development
Expenses |
$109.69 M
|
$105.62 M
|
$80.33 M
|
$57.72 M
|
$44.36 M
|
$21.23 M
|
| General & Administrative
Expenses |
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$6.72 M
|
$4.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$32.37 M
|
$30.75 M
|
$21.73 M
|
$11.25 M
|
$6.72 M
|
$4.82 M
|
| Other Expenses |
$0.00 |
$8.26 M |
$2.49 M |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$142.06 M |
$136.37 M |
$102.05 M |
$68.96 M |
$51.08 M |
$26.05 M |
| Cost And Expenses |
$142.06 M |
$136.37 M |
$102.05 M |
$68.96 M |
$51.08 M |
$26.05 M |
| Interest Income |
$10.88 M |
$5.68 M |
$2.55 M |
$1.00 M |
$495,000.00 |
$113,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$1.91 M |
$979,000.00 |
$540,000.00 |
$371,000.00 |
| Depreciation &
Amortization |
$3.45 M
|
$7.90 M
|
$7.52 M
|
$5.53 M
|
$1.79 M
|
$379,000.00
|
| EBITDA |
-$104.46 M
|
-$113.82 M
|
-$96.19 M
|
-$66.49 M
|
-$48.80 M
|
-$25.59 M
|
| EBITDA Ratio |
-3.06 |
-6.09 |
-71.99 |
-153.96 |
0 |
0 |
| Operating Income Ratio
|
-3.16
|
-6.09
|
-76.37
|
-159.37
|
0
|
0
|
| Total Other
Income/Expenses Net |
$13.71 M
|
$8.26 M
|
-$586,000.00
|
-$269,000.00
|
-$44,000.00
|
-$288,000.00
|
| Income Before Tax |
-$94.20 M |
-$108.88 M |
-$101.32 M |
-$68.80 M |
-$51.13 M |
-$26.34 M |
| Income Before Tax Ratio
|
-2.76
|
-5.66
|
-76.82
|
-160
|
0
|
0
|
| Income Tax Expense |
$4.23 M |
-$8,255.00 |
$1.91 M |
$979,000.00 |
$540,000.00 |
$83,000.00 |
| Net Income |
-$98.43 M |
-$108.87 M |
-$103.23 M |
-$69.78 M |
-$51.67 M |
-$26.34 M |
| Net Income Ratio |
-2.88 |
-5.66 |
-78.26 |
-162.28 |
0 |
0 |
| EPS |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| EPS Diluted |
-2.34 |
-2.62 |
-2.78 |
-1.9 |
-1.4 |
-1.34 |
| Weighted Average Shares
Out |
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Weighted Average Shares
Out Diluted |
$41.97 M
|
$41.59 M
|
$37.17 M
|
$36.79 M
|
$36.82 M
|
$19.63 M
|
| Link |
|
|
|
|
|
|
